Catalyst Pharmaceutical (CPRX) Tops Q3 Earnings and Revenue Estimates
Catalyst Pharmaceutical (CPRX) came out with quarterly earnings of $0.57 per share, beating the Zacks Consensus Estimate of $0.49 per share. This compares to loss of $0.24 per share a year ago.
CPRX vs. STVN: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Drugs stocks have likely encountered both Catalyst Pharmaceutical (CPRX) and Stevanato Group (STVN). But which of these two companies is the best option for those looking for undervalued stocks?
CPRX or STVN: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Catalyst Pharmaceutical (CPRX) and Stevanato Group (STVN). But which of these two stocks presents investors with the better value opportunity right now?
What Makes Catalyst (CPRX) a Good Fit for 'Trend Investing'
If you are looking for stocks that are well positioned to maintain their recent uptrend, Catalyst (CPRX) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
New Strong Buy Stocks for October 8th
CPRX, HCI, DXC, CRAI and CRUS have been added to the Zacks Rank #1 (Strong Buy) List on October 8, 2024.
CPRX or STVN: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Drugs stocks are likely familiar with Catalyst Pharmaceutical (CPRX) and Stevanato Group (STVN). But which of these two stocks is more attractive to value investors?
Catalyst (CPRX) is on the Move, Here's Why the Trend Could be Sustainable
If you are looking for stocks that are well positioned to maintain their recent uptrend, Catalyst (CPRX) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Catalyst (CPRX) Upgraded to Buy: What Does It Mean for the Stock?
Catalyst (CPRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Why Is Catalyst (CPRX) Up 8.3% Since Last Earnings Report?
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?
Wall Street Analysts See a 56.65% Upside in Catalyst (CPRX): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 56.7% in Catalyst (CPRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Recent Price Trend in Catalyst (CPRX) is Your Friend, Here's Why
If you are looking for stocks that are well positioned to maintain their recent uptrend, Catalyst (CPRX) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Catalyst Pharmaceuticals, Inc. (CPRX) Q2 2024 Earnings Call Transcript
Call End: Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX ) Q2 2024 Earnings Conference Call August 08, 2024, 08:30 AM ET Company Participants Michael Kalb - Chief Financial Officer Richard Daly - President and Chief Executive Officer Jeffrey Del Carmen - Chief Commercial Officer Steven Miller - Chief Operating Officer and Chief Scientific Officer Conference Call Participants Charles Duncan - Cantor Fitzgerald Samantha Semenkow - Citibank Jason Gerberry - Bank of America Leland Gershall - Oppenheimer & Company Joe Catanzaro - Piper Sandler Operator Greetings, and welcome to the Catalyst Pharmaceuticals' Second Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
